(Q86986567)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Herbert Loong

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

19 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

387

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

10027

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

1488-1490

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901308-2

7 January 2021

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901308-2

7 January 2021

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901308-2

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901308-2

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901308-2

7 January 2021

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901308-2

7 January 2021

10.1016/S0140-6736(15)01308-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26712085%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference